Predictors of Thirty-Day Morbidity and Unplanned Readmission after Induction Therapy Followed by Lung Resection for Non-Small Cell Lung Cancer: European Society of Thoracic Surgeons Database Analysis

Lung Cancer

Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)

Lung Cancer

Phillips WJ, Zhan LJ, Chowdhury D, Gill J, Sun A, Rittberg R, Cohen V, Gibson AJW, Yan M, Liwski D, Surapaneni S, D'Amours MF, Yu FPS, Kim Y, Qadeer RA, Dawe DE, Agulnik J, Navani V, Fung AS, Snow S, Kuruvilla S, Ho C, Lok BH, Liu G, Wheatley-Price P, Moore S

doi: 10.1016/j.lungcan.2025.108840

RECOMMENDED

Lung Cancer

Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer group

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Xenophontos E, Giaj Levra N, Durieux V, van Geffen WH, Grisay G, De la Pinta Alonso C, Arasanz H, Prisciandaro E, Ferrara R, Derks J, Von der Thusen J, Dickhoff C, Brandão M, Faivre-Finn C, Edwards J, Ruysscher D, Remon J, Dingemans AC, Berghmans T

doi: 10.1016/j.lungcan.2025.108671

Lung Cancer

Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14

ESMO Open

Frehner L, Schär S, Hayoz S, Guckenberger M, Finazzi T, Mark M, Addeo A, Mauti LA, Betticher D, Stupp R, Curioni-Fontecedro A, Peters S, Früh M, Rothschild SI, Pless M, König D, Opitz I, Ris HB, Özdemir BC, Schmid S

doi: 10.1016/j.esmoop.2025.105870

Lung Cancer

Induction Immunochemotherapy Followed by Hypo-Fractionated Radiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer

Clin Lung Cancer

Zhu Z, Wu J, Zhao L, Jiang N, Chen Y, Song X, Li M, Jiang M, Shi M, Yu S, Ren B, Yin R, Jiang F, Wang L, Kong C, Zhu X

doi: 10.1016/j.cllc.2025.01.012

COMMENTED

Lung Cancer

European Respiratory Society and European Society of Thoracic Surgeons clinical practice guideline on fitness for curative intent treatment of lung cancer

★ 3 Recommended and commented by Dr Martin Frey, Faculty Member

★ 3 Recommended and commented by Dr Marcus Hesse, Faculty Member

Eur Respir J

Brunelli A, Hardavella G, Huber RM, Berghmans T, Frille A, Rodriguez M, Tietzova I, Depypere L, Asteggiano R, Batchelor T, Costantini A, De Ruysscher D, Durieux V, Faivre-Finn C, Ferguson MK, Langer D, Marczin N, Nagavci B, Novoa N, Pompili C, Rawlinson J, Snoeckx A, Tonia T, van Geffen WH, Williams C, Caruana EJ, Kabalak PA, Mansmann U, Fallet V, Kauffmann-Guerrero D, Paesmans M, Al Tawil A, Alhannoush N, Creamer AW, Kourouni I, Blum TG

doi: 10.1183/13993003.00156-2025

RECOMMENDED

Lung Cancer

The PESGA Trial: A Prospective, Open-Label, Single-Arm, Phase II Study to Evaluate First Line Therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients, Treated by Induction Carboplatin/Etoposide/Pembrolizumab Followed by Maintenance of Pembrolizumab/ Sacituzumab Govitecan

★ 1 Recommended by Dr Martin Frey, Faculty Member

Clin Lung Cancer

Roisman LC, Mann S, Basel A, Marei R, Krayim B, Kornev G, Asna N, Peled N

doi: 10.1016/j.cllc.2025.02.002

Lung Cancer

Computer Assisted Nodule Analysis and Risk Yield Outcomes May be Associated with Recurrence after Stereotactic Body Radiation Therapy in Clinical Stage I Non-Small-Cell Lung Cancer

Clin Lung Cancer

Pham D, Thakur N, Park JA, Nie W, Correa M, Wang H, Subramanian M, Weyant M, Johnson CB, Suzuki K

doi: 10.1016/j.cllc.2025.10.008

Lung Cancer

The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study

Lung Cancer

Rolfo C, Gerber DE, Kotecha R, Ward JP, Akerley W, Weiss L, Naveh A, Shapira N, Leal T, Langer CJ, LUNAR study investigators

doi: 10.1016/j.lungcan.2025.108802

RECOMMENDED

Lung Cancer

Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis

★ 1 Recommended by Dr Martin Frey, Faculty Member

Front Oncol

Justeau G, Chouaid C, Debieuvre D, Audigier-Valette C, Quantin X, Léna H, Bosquet L, Girard N, Schoemaker MJ, Mella M, Pinto Correia B, Rault C, Daumont MJ, Penrod JR, Lee A, Pérol M

doi: 10.3389/fonc.2025.1526931

Related content

Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)

Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer group

Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14

Induction Immunochemotherapy Followed by Hypo-Fractionated Radiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer

European Respiratory Society and European Society of Thoracic Surgeons clinical practice guideline on fitness for curative intent treatment of lung cancer

The PESGA Trial: A Prospective, Open-Label, Single-Arm, Phase II Study to Evaluate First Line Therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients, Treated by Induction Carboplatin/Etoposide/Pembrolizumab Followed by Maintenance of Pembrolizumab/ Sacituzumab Govitecan

Computer Assisted Nodule Analysis and Risk Yield Outcomes May be Associated with Recurrence after Stereotactic Body Radiation Therapy in Clinical Stage I Non-Small-Cell Lung Cancer

The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study

Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis